Latest news
Respiratory Newcastle disease virus vaccine induces immunity against SARS-CoV-2 in ferrets - Bioengineer.orgBioengineer.org · Fri, 07 Aug 2026 05:33:49 GMTRLMD: Strong cash position and robust NDV-01 phase II results set stage for late-stage trials in 2026 - TradingViewTradingView · Thu, 06 Aug 2026 21:59:56 GMTRelmada Therapeutics (Nasdaq: RLMD) details Q2 2026 loss and NDV-01 Phase 3 path - Stock TitanStock Titan · Thu, 06 Aug 2026 20:41:35 GMTRELMADA THERAPEUTICS, INC. 2Q 2026: Net loss $12.9M, EPS $(0.11) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:36:00 GMTRelmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 20:15:10 GMTHarworth Group Expects EPRA NDV As At 30 June 2026 To Be Modestly Below 31 Dec 2025 Levels - TradingViewTradingView · Wed, 05 Aug 2026 06:28:00 GMTRelmada Therapeutics Appoints Bipin Dalmia as Chief Business Officer to Advance NDV-01 and Corporate Growth - Quiver QuantitativeQuiver Quantitative · Tue, 28 Jul 2026 12:45:00 GMT100 years of Newcastle disease: How a deadly poultry threat led to modern vaccine tech - foodagribusiness.worldfoodagribusiness.world · Tue, 28 Jul 2026 09:16:57 GMT